IL1RAP and acute myeloid leukemia: Targeting the extracellular portion of IL1RAP with monoclonal antibodies, IL1RAP down regulation with short hairpin RNA, and knocking out of Il1rap via genetic deletion inhibits AML growth intrinsically, through the induction of differentiation and apoptosis without affecting healthy hematopoietic cells that present a low expression of IL1RAP, and inhibit AML pathogenesis in vivo.